Trendlines Returns to Profit as Portfolio Notches Regulatory and Industry Wins

An update from Trendlines Group ( (SG:42T) ) is now available.

Trendlines Group, an Israel-based deep-tech and medtech-focused investment group, has reported a return to profitability for FY2025 based on its unaudited financial results, signalling an operational turnaround after prior losses. The company also highlighted new investments in its portfolio and provided an update on business continuity amid the situation in Israel, underscoring its efforts to maintain stability and support growth across its holdings.

The update showcased strong momentum among Trendlines’ portfolio companies, including a key FDA regulatory milestone for Phytolon that opens the door to commercialization and expanded product launches at Arcuro Medical in orthopedic repair. Additional recognition for IBI Ag, PregnanTech, and ProArc Medical from global competitions and industry awards reinforces the strength and visibility of Trendlines’ portfolio, potentially enhancing its industry positioning and long-term value for stakeholders.

The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.

More about Trendlines Group

Trendlines Group is an Israel-based investment group that develops and invests in early-stage technology companies, with a particular emphasis on medical devices, agrifood tech, and other deep-tech innovations. Through its network of portfolio companies, Trendlines focuses on commercializing novel solutions for healthcare, agriculture, and related markets, aiming to create value via technological differentiation and regulatory advancement.

Average Trading Volume: 9,540,891

Technical Sentiment Signal: Hold

Current Market Cap: S$87.33M

See more insights into 42T stock on TipRanks’ Stock Analysis page.